RJF Stock Overview
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for RJF from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.56 |
| 52 Week High | €3.38 |
| 52 Week Low | €2.20 |
| Beta | 0.89 |
| 1 Month Change | -9.86% |
| 3 Month Change | -6.23% |
| 1 Year Change | 9.40% |
| 3 Year Change | -23.81% |
| 5 Year Change | 1.59% |
| Change since IPO | -32.98% |
Recent News & Updates
Recent updates
Calculating The Fair Value Of Laboratorio Reig Jofre, S.A. (BME:RJF)
Jun 22
These 4 Measures Indicate That Laboratorio Reig Jofre (BME:RJF) Is Using Debt Extensively
Feb 02This Analyst Just Downgraded Their Laboratorio Reig Jofre, S.A. (BME:RJF) EPS Forecasts
Mar 07We Think Laboratorio Reig Jofre (BME:RJF) Is Taking Some Risk With Its Debt
Mar 07Laboratorio Reig Jofre (BME:RJF) Seems To Use Debt Quite Sensibly
May 17The Laboratorio Reig Jofre (BME:RJF) Share Price Has Gained 146%, So Why Not Pay It Some Attention?
Mar 07Is Laboratorio Reig Jofre (BME:RJF) Using Too Much Debt?
Jan 14Laboratorio Reig Jofre (BME:RJF) Shareholders Booked A 47% Gain In The Last Year
Dec 05Shareholder Returns
| RJF | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | -5.9% | -1.1% | -1.2% |
| 1Y | 9.4% | 3.6% | 12.3% |
Return vs Industry: RJF exceeded the Spanish Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: RJF underperformed the Spanish Market which returned 12.1% over the past year.
Price Volatility
| RJF volatility | |
|---|---|
| RJF Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.0% |
| 10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: RJF has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: RJF's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,323 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| RJF fundamental statistics | |
|---|---|
| Market cap | €204.95m |
| Earnings (TTM) | €9.55m |
| Revenue (TTM) | €333.69m |
21.5x
P/E Ratio0.6x
P/S RatioIs RJF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RJF income statement (TTM) | |
|---|---|
| Revenue | €333.69m |
| Cost of Revenue | €144.54m |
| Gross Profit | €189.15m |
| Other Expenses | €179.60m |
| Earnings | €9.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 56.68% |
| Net Profit Margin | 2.86% |
| Debt/Equity Ratio | 24.7% |
How did RJF perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 06:28 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Laboratorio Reig Jofre, S.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francisco Ruiz | BNP Paribas Exane |
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |